Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension [Phase 3]

View source ↗

Summary

Open-label extension of a Phase 3 trial evaluating risperidone ISM in acute schizophrenia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Risperidone ISM (risperidone)

Snippet

Sponsor: Rovi Pharmaceuticals Laboratories | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2022-02-23